By admin 
For decades, the APOE4 gene variant has been recognized as a formidable genetic determinant of Alzheimer’s disease risk. Approximately one in four individuals carries at least one copy of APOE4, and it is estimated to be present in 60 to 75 percent of all Alzheimer’s patients. This makes APOE4 a critical target for understanding the disease’s origins. While the presence of APOE4 significantly elevates risk, the precise mechanisms through which it precipitates neurodegeneration have remained a complex puzzle. Previous research hinted at early, subtle alterations in brain function, but the molecular sequence linking APOE4 to these initial changes and subsequent cognitive decline was largely undefined—until now.
Researchers at Gladstone Institutes, led by Dr. Misha Zilberter and Dr. Yadong Huang, have meticulously mapped out a molecular sequence that could explain these nascent effects. Their groundbreaking work, published in the esteemed journal Nature Aging, utilized sophisticated mouse models to unravel the intricate cellular and molecular events downstream of APOE4. What they uncovered was a cascade initiated by APOE4 that leads to profound changes in neuronal architecture and activity, setting the stage for future memory impairments.
The core finding reveals that APOE4 significantly boosts the production of a protein named Nell2 (Neural Epidermal growth factor-like like protein 2). This increase in Nell2 levels has a direct and detrimental impact on neurons: it causes them to become physically smaller and, critically, unusually hyperactive. This neuronal hyperactivity, characterized by excessive firing and heightened excitability, was not merely an incidental observation. The study established a clear correlative link: mice exhibiting the greatest brain hyperactivity in their youth later developed the most severe memory problems as they aged. This predictive power underscores the importance of these early alterations as potential biomarkers for future cognitive decline.
"To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages," states Misha Zilberter, PhD, principal staff research scientist at Gladstone and a senior author of the study. "We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages." This statement highlights the dual significance of the research: identifying early, preclinical changes and establishing their prognostic value.
A Major Genetic Risk Factor for Alzheimer’s: The APOE Story
The APOE gene exists in three common forms, or alleles: APOE2, APOE3, and APOE4. APOE3 is the most common allele and is considered neutral in terms of Alzheimer’s risk. APOE2 is associated with a reduced risk, while APOE4 is unequivocally linked to an increased risk and an earlier age of onset for Alzheimer’s disease. Individuals inheriting one copy of APOE4 have a three-to-fourfold increased risk, while those with two copies face a ten-to-fifteenfold increased risk.
The APOE protein plays a crucial role in lipid metabolism, particularly in the transport of cholesterol and other fats in the brain. In the context of Alzheimer’s, APOE4 is implicated in several pathological processes. It is less efficient at clearing amyloid-beta (Aβ) peptides from the brain, leading to their accumulation and the formation of amyloid plaques, a hallmark of Alzheimer’s. APOE4 also exacerbates tau pathology, promotes neuroinflammation, and directly impairs synaptic function and neuronal plasticity. The current study adds another critical layer to this understanding by demonstrating its direct impact on neuronal excitability through Nell2.
"This study is a big breakthrough for the field of Alzheimer’s research," comments Yadong Huang, MD, PhD, associate director of the Gladstone Institute of Neurological Disease and a senior author of the study. "It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase risk of cognitive decline, and to the development of therapies that could block the detrimental effects of APOE4 early on." Dr. Huang’s perspective emphasizes the translational potential of these findings, suggesting a paradigm shift in therapeutic strategies towards pre-symptomatic intervention.
APOE4 Makes Memory Circuits Hyperactive Early: The Mechanism of Dysfunction
The concept of early brain hyperactivity in APOE4 carriers is not entirely new. Prior neuroimaging studies in humans using functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) have observed signs of unusually high brain activity, particularly in the hippocampus, in cognitively normal APOE4 carriers even before middle age. This early hyperactivity has been consistently associated with later cognitive decline, suggesting it’s not a benign phenomenon but rather an early pathological manifestation. However, the cellular and molecular underpinnings of how APOE4 instigates these changes and why they contribute to memory problems later in life remained largely enigmatic.
To dissect this phenomenon, the Gladstone team meticulously analyzed recordings of brain activity in young mice carrying the APOE4 gene and examined individual neurons from their brains. The results were stark: young APOE4 mice displayed excessive neuronal activity within two specific subregions of the hippocampus—the dentate gyrus and CA3—both critical for memory formation and retrieval. This observation directly mirrors findings in human APOE4 carriers, where these same hippocampal regions are frequently found to be hyperactive.
"We found that the extent of hyperactivity in young mice predicted how poorly they performed on spatial learning and memory tests later in life," explains Dennis Tabuena, PhD, a scientist co-mentored by Zilberter and Huang, and first author of the new paper. This direct link between early neuronal dysfunction and later behavioral deficits is a powerful indicator of the pathological trajectory initiated by APOE4.
Further comparative analysis with mice carrying APOE3, the "neutral" allele, provided crucial insights into the accelerated aging hypothesis. Neurons in the affected hippocampal regions were notably smaller in APOE4 mice compared to APOE3 mice. Smaller neurons inherently possess higher input resistance, making them more excitable and prone to excessive firing. While APOE3 mice also showed an increase in hippocampal neuron excitability, this shift only occurred in old age, aligning with normal aging processes.
"This suggests APOE4 accelerates a process that resembles normal aging, and could explain why people with the gene variant are more likely to develop Alzheimer’s disease earlier in life," Huang posits. This hypothesis provides a compelling framework for understanding the accelerated pathology observed in APOE4 carriers. The constant overstimulation and metabolic stress imposed by chronic hyperactivity could lead to neuronal exhaustion, synaptic dysfunction, and eventually, neuronal damage and loss, mirroring an accelerated aging process.
The Effect Comes From APOE4 Inside Neurons: A Paradigm Shift
One of the most surprising and impactful findings of this study challenges a long-held assumption in Alzheimer’s research regarding the cellular origin of APOE4‘s detrimental effects. Historically, most APOE in a healthy brain is produced by astrocytes, star-shaped glial cells that provide metabolic and structural support to neurons. Consequently, researchers largely suspected that astrocytic APOE4 was the primary driver of its pathological connection to Alzheimer’s risk.
However, the new results point in a dramatically different direction for this specific hyperactivity pathway. The study definitively demonstrated that the hippocampal hyperactivity associated with APOE4 was entirely driven by APOE4 produced within neurons themselves, not by astrocytes.
"When we deleted the APOE4 gene from astrocytes, nothing changed," Zilberter confirms. "But when we deleted it from neurons, the cells became larger and started functioning normally again." This finding represents a significant paradigm shift, suggesting that while astrocytic APOE4 may contribute to other aspects of Alzheimer’s pathology (e.g., amyloid clearance), the early neuronal hyperactivity identified in this study is a direct consequence of neuronal APOE4. This re-focuses research efforts on neuron-intrinsic mechanisms of APOE4 pathology.
Nell2 Emerges as a Possible Treatment Target: A Glimmer of Hope
With the cellular origin identified, the researchers embarked on uncovering the precise molecular process responsible for making APOE4 neurons smaller and more excitable. Through meticulous analysis of gene activity patterns in individual cells across various hippocampal cell types, one molecule repeatedly stood out: Nell2. This protein appeared at unusually high levels specifically in neurons carrying APOE4.
Nell2 is a secreted glycoprotein known to play roles in neuronal development, synaptic plasticity, and cell survival. Its overexpression, as observed in APOE4 neurons, appears to disrupt the delicate balance of neuronal function, leading to the observed morphological and physiological changes.
To confirm Nell2’s causative role, the researchers employed CRISPRi (CRISPR interference), a cutting-edge method that lowers the activity of a specific gene without permanently altering the DNA sequence. By using CRISPRi to reduce Nell2 levels in hippocampal neurons from adult APOE4 mice, they observed a remarkable transformation: the neurons became larger and less excitable, essentially returning towards their normal size and firing behavior. This compelling result strongly indicates that elevated Nell2 is indeed responsible for the excessive neuronal activity seen in brains carrying APOE4.
While Nell2 had not previously been directly investigated in connection with APOE4, earlier research had noted elevated levels of the protein in the brains of human Alzheimer’s patients, with higher amounts correlating with poorer cognitive function. This existing human data provides crucial translational context for the current mouse model findings, suggesting that Nell2 dysregulation might be a conserved pathological feature in human Alzheimer’s.
"What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level," Huang emphasizes. "That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered." This statement carries immense therapeutic promise. The ability to reverse pathological changes in adult mice, rather than solely preventing them in younger animals, suggests that Nell2-targeting therapies could be effective even in individuals who have already begun to experience the subtle, preclinical stages of APOE4-associated Alzheimer’s.
Future Directions and Clinical Promise
The implications of this research are profound. First, it provides a tangible molecular target for therapeutic development. Future drugs designed to specifically lower Nell2 production or block its activity could potentially mitigate the early neuronal hyperactivity and, consequently, delay or prevent cognitive decline in APOE4 carriers. This could involve small molecule inhibitors, gene therapies, or even antibody-based approaches.
Second, the study highlights the importance of early intervention. If neuronal hyperactivity is a precursor to later memory problems, then identifying and addressing this dysfunction early, perhaps even before overt cognitive symptoms appear, could be crucial. This opens avenues for developing early diagnostic biomarkers based on Nell2 levels or specific patterns of brain hyperactivity in APOE4 carriers.
Finally, the re-evaluation of APOE4‘s cellular origin in driving this specific pathology redirects research efforts. Understanding that neuronal APOE4 plays a direct role in neuronal hyperactivity provides a more focused target for developing therapies that specifically modulate neuronal function, rather than solely focusing on glial cells. This doesn’t diminish the role of astrocytes in other aspects of APOE4 pathology but refines our understanding of distinct pathways.
While the findings from mouse models are incredibly promising, the journey from preclinical research to human clinical trials is complex and lengthy. However, the clarity of the molecular pathway, the predictive power of the early changes, and the demonstrated reversibility of the pathology offer a beacon of hope for the millions worldwide living with the elevated risk of Alzheimer’s due to their APOE4 genotype. This research funded by significant grants from the National Institute on Aging, National Institute of Neurological Disorders and Stroke, and National Center for Research Resources, represents a monumental step forward in our quest to understand, prevent, and ultimately conquer Alzheimer’s disease.
